Wizcure Pharmaa Private Limited is subject to a Class II drug recall initiated by the FDA for its Fluorescein Sodium Ophthalmic Strips (1mg, 100-count and 300-count boxes, NDC 83851-100-10 and 83851-100-30). The recall is due to a lack of assurance of sterility, stemming from the product not being manufactured in conformance with current Good Manufacturing Practices (cGMP).

This recall signifies a critical failure in manufacturing quality control. Wizcure Pharmaa must immediately cease distribution, notify all relevant parties, and implement a recall plan to retrieve affected products from the market. The FDA's classification as 'Ongoing' suggests active management of the recall process. Failure to comply with recall procedures can result in further enforcement actions and penalties.